Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
143M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
59.9M
-
Shares change
-
+894K
-
Total reported value, excl. options
-
$537M
-
Value change
-
+$3.88M
-
Put/Call ratio
-
0.02
-
Number of buys
-
56
-
Number of sells
-
-44
-
Price
-
$8.96
Significant Holders of Dyne Therapeutics, Inc. - Common Stock (DYN) as of Q3 2023
134 filings reported holding DYN - Dyne Therapeutics, Inc. - Common Stock as of Q3 2023.
Dyne Therapeutics, Inc. - Common Stock (DYN) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.9M shares
of 143M outstanding shares and own 42.02% of the company stock.
Largest 10 shareholders include Atlas Venture Life Science Advisors, LLC (9.89M shares), MPM ASSET MANAGEMENT LLC (4.95M shares), BlackRock Inc. (3.31M shares), CITADEL ADVISORS LLC (3.04M shares), Deep Track Capital, LP (2.4M shares), VANGUARD GROUP INC (2.36M shares), Vida Ventures Advisors, LLC (2.22M shares), Logos Global Management LP (2.18M shares), VR Adviser, LLC (2.17M shares), and STATE STREET CORP (1.94M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.